
Abbott (NYSE:ABT) said it won approval from the Japanese Ministry of Health, Labor and Welfare for its next-generation Xience Prime coronary stent
The nod means the cobalt-chromium stent is "available in all of the major markets worldwide," according to a press releaase, including the U.S., Europe, China and India.
The drug-eluting stent is at the vanguard of a new breed of stents that are thinner and more visible under X-ray.
"Xience Prime leverages the best of Xience V, which is the market-leading drug eluting stent in Japan and throughout the world, and the introduction of Xience Prime further advances Abbott’s leadership position," Robert Hance, senior vice president, vascular, said in prepared remarks.

Teleflex wins CE Mark for Arrow VPS
Teleflex (NYSE:TFX) said its VasoNova subsidiary won CE Mark approval in the European Union for the Arrow VPS catheter placement system. Read more
OSI’s Spacelabs wins 510(k) for qube monitor
OSI Systems (NSDQ:OSIS) subsidiary Spacelabs Healthcare won 510(k) clearance from the FDA for its qube compact patient monitoring system. Read more
Arteriocyte wins FDA nod for IDE trial
Arteriocyte said it won investigational device exemption approval from the FDA for a Phase I clinical trial of its Magellan MAR01 technology in treating compartment syndrome. Read more
SastoMed wins CE Mark for wound spray
SastoMed GmbH won CE Mark approval for its Granulox wound spray. Read more
C8 Medisensors files for CE Mark
C8 MediSensors said it filed for CE Mark approval for its optical glucose monitor in Europe. Read more